Fulminant hepatitis following COVID‐19 vaccination: A case report
Abstract The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-07-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.6066 |
| _version_ | 1828777365596012544 |
|---|---|
| author | Mohammad Barary Athena Sharifi‐Razavi Nasser Rakhshani Terence T. Sio Soheil Ebrahimpour Mana Baziboroun |
| author_facet | Mohammad Barary Athena Sharifi‐Razavi Nasser Rakhshani Terence T. Sio Soheil Ebrahimpour Mana Baziboroun |
| author_sort | Mohammad Barary |
| collection | DOAJ |
| description | Abstract The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis. |
| first_indexed | 2024-12-11T16:19:14Z |
| format | Article |
| id | doaj.art-7b022e39b36a4f7b9e72f23cc29b921b |
| institution | Directory Open Access Journal |
| issn | 2050-0904 |
| language | English |
| last_indexed | 2024-12-11T16:19:14Z |
| publishDate | 2022-07-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical Case Reports |
| spelling | doaj.art-7b022e39b36a4f7b9e72f23cc29b921b2022-12-22T00:58:52ZengWileyClinical Case Reports2050-09042022-07-01107n/an/a10.1002/ccr3.6066Fulminant hepatitis following COVID‐19 vaccination: A case reportMohammad Barary0Athena Sharifi‐Razavi1Nasser Rakhshani2Terence T. Sio3Soheil Ebrahimpour4Mana Baziboroun5Student Research Committee, Virtual School of Medical Education and Management Shahid Beheshti University of Medical Sciences Tehran IranClinical Research Development Unit of Bou‐Ali Sina Hospital Mazandaran University of Medical Sciences Sari IranDepartment of Pathology, Gastrointestinal and Liver Diseases Research Centre, Firoozgar Hospital Iran University of Medical Sciences Tehran IranDepartment of Radiation Oncology Mayo Clinic Phoenix Arizona USAInfectious Diseases and Tropical Medicine Research Center, Health Research Institute Babol University of Medical Sciences Babol IranInfectious Diseases and Tropical Medicine Research Center, Health Research Institute Babol University of Medical Sciences Babol IranAbstract The common side effects of COVID‐19 vaccination were mostly self‐restricted local reactions that quickly resolved. Nevertheless, rare autoimmune hepatitis cases have been reported in some vaccinated with mRNA COVID‐19 vaccines. This article presents a young man who developed fulminant hepatitis a few days after vaccination with the first dose of the AstraZeneca COVID‐19 vaccine. A 35‐year‐old man was admitted to our hospital with generalized weakness, abdominal pain, and jaundice. He received the first dose of the AstraZeneca COVID‐19 vaccine 8 days earlier. He was admitted to the hospital with a chief complaint of abdominal pain. On admission and because of his high D‐dimers, low platelet count, and low Fibrinogen level, vaccine‐induced immune thrombosis thrombocytopenia was suspected, which was ruled out later. Then, after a surge in his liver function tests, decreasing platelet, and abnormal clotting tests, fulminant hepatitis was considered for this patient. Several bacterial, viral, and autoimmune etiologies were then suspected, with all ruled out. Thus, fulminant hepatitis secondary to his AstraZeneca COVID‐19 vaccine was confirmed. Unfortunately, he died 3 days later of disseminated intravascular coagulopathy, after which a liver necropsy was performed, indicating drug/toxin‐induced hepatitis.https://doi.org/10.1002/ccr3.6066AstraZenecaCOVID‐19hepatitisSARS‐CoV‐2vaccine, fulminant |
| spellingShingle | Mohammad Barary Athena Sharifi‐Razavi Nasser Rakhshani Terence T. Sio Soheil Ebrahimpour Mana Baziboroun Fulminant hepatitis following COVID‐19 vaccination: A case report Clinical Case Reports AstraZeneca COVID‐19 hepatitis SARS‐CoV‐2 vaccine, fulminant |
| title | Fulminant hepatitis following COVID‐19 vaccination: A case report |
| title_full | Fulminant hepatitis following COVID‐19 vaccination: A case report |
| title_fullStr | Fulminant hepatitis following COVID‐19 vaccination: A case report |
| title_full_unstemmed | Fulminant hepatitis following COVID‐19 vaccination: A case report |
| title_short | Fulminant hepatitis following COVID‐19 vaccination: A case report |
| title_sort | fulminant hepatitis following covid 19 vaccination a case report |
| topic | AstraZeneca COVID‐19 hepatitis SARS‐CoV‐2 vaccine, fulminant |
| url | https://doi.org/10.1002/ccr3.6066 |
| work_keys_str_mv | AT mohammadbarary fulminanthepatitisfollowingcovid19vaccinationacasereport AT athenasharifirazavi fulminanthepatitisfollowingcovid19vaccinationacasereport AT nasserrakhshani fulminanthepatitisfollowingcovid19vaccinationacasereport AT terencetsio fulminanthepatitisfollowingcovid19vaccinationacasereport AT soheilebrahimpour fulminanthepatitisfollowingcovid19vaccinationacasereport AT manabaziboroun fulminanthepatitisfollowingcovid19vaccinationacasereport |